Beyond Air, Inc. (XAIR)
| Market Cap | 2.18M -84.1% |
| Revenue (ttm) | 7.69M +60.7% |
| Net Income | -33.49M |
| EPS | -62.88 |
| Shares Out | 984.41K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,166 |
| Open | 2.140 |
| Previous Close | 2.100 |
| Day's Range | 2.070 - 2.240 |
| 52-Week Range | 2.050 - 55.000 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 20.00 (+804.98%) |
| Est. Earnings | Nov 9, 2026 |
About XAIR
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-h... [Read more]
Financial Performance
In fiscal year 2026, Beyond Air's revenue was $7.68 million, an increase of 107.26% compared to the previous year's $3.71 million. Losses were -$33.25 million, -28.69% less than in 2025.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for XAIR stock is "Buy." The 12-month stock price target is $20.0, which is an increase of 804.98% from the latest price.
News
Beyond Air reports preliminary Q3 revenue $2.3M
The preliminary revenue represents an increase of approximately 30% compared with the quarter ended June 30 and 27% compared with the same quarter last year, and reflects the rollout of…
Beyond Air backs FY26 revenue view $8M, consensus $8M
The company said, “The Company reaffirms its previously issued revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation LungFit PH system.” Published fi...
Beyond Air backs FY27 revenue view $16M-$18M, consensus $16.72M
The company said, “The Company also reaffirms its revenue guidance of $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending F...
Beyond Air® Preannounces Preliminary Revenue for the Quarter Ended September 30, 2026
Preliminary revenue of $2.3 million represents the highest quarterly revenue reported, and approximately 30% sequential quarterly growth and 27% growth over the same period last year Performance refle...
Beyond Air Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
LungFit's hospital-focused nitric oxide delivery system addresses major logistical challenges and is poised for significant market expansion with its Generation 2 device, which enables patient transport and quadruples the addressable market. FDA approval is expected by year-end, with immediate deployment planned and strong financial backing to support the launch.
Beyond Air to Participate in the 2026 Cantor Global Healthcare Conference
GARDEN CITY, N.Y., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (...
Beyond Air initiated with a Buy at Lake Street on durable recurring revenue
As previously reported, Lake Street initiated coverage of Beyond Air (XAIR) with a Buy rating and $10 price target The commercial-stage medical device company is built around LungFit, an inhaled…
Beyond Air initiated with a Buy at Lake Street
Lake Street analyst Frank Takkinen initiated coverage of Beyond Air (XAIR) with a Buy rating and $10 price target
Beyond Air gets Breakthrough Device Designation for LungFit GO
Beyond Air (XAIR) announced that the FDA has granted Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease.
Beyond Air® Receives FDA Breakthrough Device Designation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)
GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air to sell NeuroNOS stake to Univo Pharmaceutical
Beyond Air (XAIR) announced that they have entered into a definitive agreement under which Univo Pharmaceutical Industries will acquire control over the outstanding shares of NeuroNOS Israel. The tran...
Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone Payments
Beyond Air to receive shares representing 19.99% of Univo's issued and outstanding share capital upon closing Beyond Air eligible to receive up to $32.5 million in development and commercial milestone...
Beyond Air Slides: Corporate presentation
Beyond Air has posted slides in relation to its latest quarterly earnings report, which was published on August 25, 2026.
Beyond Air files to sell 5.42M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 5.42M shares of common stock. The company is not selling any…
Beyond Air Registration statement: Registration filing
Beyond Air filed a registration statement on August 17, 2026, providing details about a securities offering with the SEC.
Beyond Air Earnings Call Transcript: Q1 2027
Revenue remained flat at $1.8 million, but gross margin improved to 13% and the commercial pipeline doubled. Guidance for 2026 is reaffirmed at $8 million, with significant growth expected in 2027 pending FDA approval of Gen 2 LungFit PH.
Beyond Air Earnings release: Q1 2027
Beyond Air released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
Beyond Air Quarterly report: Q1 2027
Beyond Air has published its Q1 2027 quarterly earnings report on August 13, 2026.
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027
Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026
GARDEN CITY, N.Y., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
GARDEN CITY, N.Y., July 30, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harness...
Beyond Air trading halted, news pending
19:50 EDT Beyond Air (XAIR) trading halted, news pending
Beyond Air Earnings Call Transcript: Q4 2026
Revenue more than doubled to $7.7M in fiscal 2026, driven by strong LungFit PH adoption and high renewal rates. Guidance for 2026 is $8M, with 2027 expected to reach $16–18M, assuming Gen 2 approval and launch. Gen 2 is anticipated to significantly expand the addressable market.
Beyond Air Earnings release: Q4 2026
Beyond Air released its Q4 2026 earnings on June 26, 2026, summarizing the period's financial results.
Beyond Air Annual report: Q4 2026
Beyond Air has published its Q4 2026 annual report on June 26, 2026.